CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD.
BACKGROUND
European Group for Blood and Marrow Transplantation (EBMT) registry data indicate that patients with relapsed HD given high-dose therapy (HDT), supported with PBPC might have a poorer outcome compared with those given BM. Since this can be due to the infusion of contaminating tumor cells in the PBPC products, we studied the presence of minimal residual disease and tested whether CD34(+) cell enrichment was able to remove atypical CD30(+) cells from PBPC grafts.


METHODS
Eighteen HD patients eligible for HDT were included in the study. By the use of immunocytochemistry (ICC), mononuclear cells from BM and peripheral blood (PB) before mobilization, PBPC products and selected CD34(+) fractions were stained using anti-CD30 MAb (Ber-H2) and the APAAP (alkaline phosphatase-anti-alkaline phosphatase) method. Cells scored as atypical CD30(+) cells were large- to medium-sized, with membranous, cytoplasmatic and/or Golgi positivity for CD30.


RESULTS
Nine out of 11 BM tested were positive, while 14 of 14 PB and 18 of 18 PBPC contained atypical CD30(+) cells. The total number of atypical CD30(+) cells was significantly higher in PBPC than in the corresponding BM. CD34(+) cell enrichment employing ISOLEX 300I gave a purity and yield of 99.2% (range 97.8-99.7) and 49.6% (range 30.0-78.4), respectively. After HDT a median of 5.8 x 10(6) (range 2.7-20) CD34(+) cells/kg was infused. Neutrophil counts of > 0.5 x 10(9)/L and platelet counts of > 20 x 10(9)/L were achieved at Day 12 (range 10-17) and at Day 10 (range 7-15), respectively. Sixteen of 18 CD34(+) selected products had no detectable atypical CD30(+) cells, while two had a low number. After HDT, the overall survival was 80% and the event-free survival was 69%, with a median follow-up of 24 months (range 1-36).


CONCLUSIONS
We show that contaminating atypical CD30(+) cells in PBPC can efficiently be removed by CD34(+) cell enrichment, and the use of such grafts following HDT gives fast and sustained engraftment.
Blystad
A K
AK
Department of Oncology, The Norwegian Radium Hospital, Oslo, Norway.
Torlakovic
E
E
Holte
H
H
Kvaløy
S
S
Lenschow
E
E
Kvalheim
G
G
D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000276:immunology*; D015415:Biomarkers / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000276:immunology; D001854:Bone Marrow Cells / Q000276:immunology / Q000473:pathology; D002648:Child; D005260:Female; D006085:Graft Survival / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006689:Hodgkin Disease / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007150:Immunohistochemistry / Q000295:instrumentation / Q000379:methods*; D018189:Immunomagnetic Separation / Q000295:instrumentation / Q000379:methods*; D017730:Ki-1 Antigen / Q000276:immunology*; D008214:Lymphocytes / Q000166:cytology / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating / Q000276:immunology* / Q000473:pathology; D017713:Platelet Transfusion; D012008:Recurrence; D015996:Survival Rate; D016896:Treatment Outcome
D018952:Antigens, CD34; D015415:Biomarkers; D014408:Biomarkers, Tumor; D017730:Ki-1 Antigen